Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics of LY3314814 in Subjects With Hepatic Impairment

Trial Profile

Pharmacokinetics of LY3314814 in Subjects With Hepatic Impairment

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 06 Jul 2018

At a glance

  • Drugs Lanabecestat (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 26 Jun 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 10 May 2018 Planned initiation date changed from 1 May 2018 to 1 Jun 2018.
    • 19 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top